Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives

Up to 90% of patients with tuberous sclerosis complex (TSC) have epilepsy, and in over half of patients seizure control cannot be achieved by regular antiepileptic drugs. The underlying problem is mTOR hyperactivation due to loss of function of the TSC proteins. Treatment with everolimus, an mTOR in...

Descripción completa

Detalles Bibliográficos
Autores principales: Overwater, Iris E, Rietman, André B, van Eeghen, Agnies M, de Wit, Marie Claire Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6666377/
https://www.ncbi.nlm.nih.gov/pubmed/31440057
http://dx.doi.org/10.2147/TCRM.S145630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6666377/
https://www.ncbi.nlm.nih.gov/pubmed/31440057
http://dx.doi.org/10.2147/TCRM.S145630

Ejemplares similares